Crossing the Chasm to Commercialization
Abstract
DermiSense seeks to disrupt the status quo by replacing expensive and resource-intensive blood sampling with an innovative low-cost, zero-power patch that extracts dermal interstitial fluid for local analysis or rapid lab tests. This approach simplifies patient care by offering a more accessible and potentially cost-effective solution. As DermiSense moves toward commercialization, it faces the "valley of death"— a critical phase where securing funding, navigating regulatory approvals, and establishing a cost effective manufacturing process become paramount to achieving market adoption. DermiSense is dedicated to methodically addressing the hurdles it will encounter as it advances one step closer to market readiness.
Biography
John Strang brings a unique blend of leadership from fields in virtual healthcare and quality management in manufacturing. His experience includes spearheading the development of a web-based application designed for the stringent demands of quality control in medical device and aerospace manufacturing, and a strategic role in driving revenue growth within the virtual healthcare industry at Vida Health. John has proven his ability to lead teams towards innovation and market success. His diverse background, which spans from tech startups to major league sports, emphasizes his adaptable and forward-thinking approach to leadership. John's operational expertise and product management skills have consistently resulted in enhanced cross-departmental collaboration, productivity, and successful product launches.